Skip to main content
Humira Clobbers Biosimilars in Battle for Part D Coverage

Researchers found nearly all Medicare Part D plans cover ori

Dr. John Cush RheumNow

2 years 2 months ago
Humira Clobbers Biosimilars in Battle for Part D Coverage Researchers found nearly all Medicare Part D plans cover original adalimumab (Humira), but only about half cover approved biosimilars. https://t.co/mpkypge1rE https://t.co/qRvtg4IM8c
Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatolog

Dr. Antoni Chan synovialjoints

2 years 2 months ago
Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz
Nice idea from Erlangen: B cell then T cell suppression for ACPA+ RA. A tolergenic reset of sorts. Sounds interesting…

David Liew drdavidliew

2 years 2 months ago
Nice idea from Erlangen: B cell then T cell suppression for ACPA+ RA. A tolergenic reset of sorts. Sounds interesting… small study, but sadly no difference over ritux only. Does seem broadly safe though - maybe will be a strategy for another disease! #EULAR2024 OP0069 @RheumNow https://t.co/mXUS4kpRCK
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill s

Dr. Antoni Chan synovialjoints

2 years 2 months ago
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o
OP0053 #EULAR2024 @RheumNow #EULARBest
Effect of #RTX in preclinical #RheumatoidArthritis

RA-risk pts given 1 dose PBO

Mrinalini Dey DrMiniDey

2 years 2 months ago
OP0053 #EULAR2024 @RheumNow #EULARBest Effect of #RTX in preclinical #RheumatoidArthritis RA-risk pts given 1 dose PBO or 1000mg RTX RTX in RA-risk pts delayed onset of RA by 1yr; no benefit on QoL Pts developing RA: RTX didn't alter PROs or disease severity when developing RA
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most

David Liew drdavidliew

2 years 2 months ago
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure

Dr. Antoni Chan synovialjoints

2 years 2 months ago
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased pree

Bella Mehta bella_mehta

2 years 2 months ago
Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow
AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA

Not a single blink of difference.
Maybe for high CCP titr

David Liew drdavidliew

2 years 2 months ago
AMPLIFIED study: abatacept vs adalimumab in RF+ACPA+ early RA Not a single blink of difference. Maybe for high CCP titre but the inverse for low CCP. Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007 @RheumNow https://t.co/IswCub9lLn
Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and

Bella Mehta bella_mehta

2 years 2 months ago
Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn
Treat to target in #lupus - difficult for many reasons.
Also may be too much of a restrictive strategy.
@Lupusreferenc

Bella Mehta bella_mehta

2 years 2 months ago
Treat to target in #lupus - difficult for many reasons. Also may be too much of a restrictive strategy. @Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
Measure Hydroxychloroquine levels! @RheumNow

Bella Mehta bella_mehta

2 years 2 months ago
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session. Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
×